Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b GS-9820 in lymphoid malignancies
NL-OMON39586Phase 1Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of acalisib in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and Hodgkin lymphoma (HL), sponsored by Gilead Sciences. Primary endpoint: Maximum tolerated dose. Started Nov 2012; status: active, not recruiting.
02
Drugs
acalisib
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NL-OMON39586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39586.